Northwest Biotherapeutics Inc has recently completed the acquisition of Advent BioServices Ltd., a UK-based CDMO, integrating critical manufacturing assets and intellectual property to support its DCVax® platform targeting solid tumors. This strategic move consolidates development, production, and cryostorage under one subsidiary, potentially improving operational control and cost structure. However, as of Q1 2026, the company faces severe liquidity constraints with a current ratio of approximately 0.07 and a net debt position exceeding $57 million. Growth prospects hinge on regulatory approvals and successful commercialization of DCVax®, yet significant risks include capital intensity, clinical development hurdles, and financial leverage.